Expensive Oral Agents Responsible for Cost Shifting in Cancer - Drug Pricing Lab

Expensive Oral Agents Responsible for Cost Shifting in Cancer

The American Journal of Managed Care
April 29, 2016

Oral anticancer agents are being launched at significantly higher prices compared with a decade ago, which can prove a barrier to patient access, according to a new analysis published in JAMA Oncology.
Read Full Article Here